Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Initiates PMA Submission for Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Epigenomics today announced it has submitted the first module of its premarket approval application for the second generation of its colorectal cancer screening test to the US Food and Drug Administration.

The first module for the Epi proColon test was submitted on Dec. 30, 2011 and includes documentation on the manufacturing and quality controls section related to the test. Additional modules are expected to be submitted to FDA during the current and second quarters. The final module, which will include all clinical data, is scheduled for submission during the second half of 2012, the company said.

FDA provides for a 90-day review period for each module.

For its clinical module, Epigenomics will need to demonstrate that Epi proColon performs at least as well as fecal immunochemical testing, it said, adding that it has been in discussions with FDA about the design for its clinical study, which it expects to initiate in the coming months after the study's protocol has been finalized.

The clinical module for the PMA submission will include results of the head-to-head comparison with fecal immunochemical testing, previously announced data from a clinical validation study in a cohort of prospectively collected samples, and other clinical study results.

Last month, the Berlin, Germany-based molecular diagnostics firm announced clinical validation study results for the test. The test demonstrated 68 percent sensitivity and 80 percent specificity.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.